This study examined the effects of darapladib, a selective lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) inhibitor, on biomarkers of cardiovascular (CV) risk.
rupture) are accompanied by focal inflammation in lesionprone areas (2) . In addition, elevated levels of circulating inflammatory biomarkers have been reported in several populations at risk (3, 4) . Recent clinical trials further implied that achieving lower levels of high-sensitivity C-reactive protein (hs-CRP) in conjunction with aggressive low-density lipoprotein cholesterol (LDL-C)-lowering (Ͻ70 mg/dl) are associated with reduced progression of coronary atheroma and fewer CV events (5, 6) . Nevertheless, statin trials offer only indirect evidence of the link between inflammation and clinical events because of the primary benefit of concomitant lipid-lowering (7) . Other treatments that are proven to reduce CV events lack consistent antiinflammatory effects in the clinical setting (e.g., aspirin or angiotensin-converting enzyme inhibitors) (8) . Thus, the causal role of inflammation in the progression of atherosclerotic vascular disease and CV events remains to be proven by pharmacologic interventions that specifically target the inflammatory cascade.
Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is an emerging biomarker of CV risk that is pharmacologically modifiable and therefore well positioned to address novel mechanisms of atherosclerotic vascular disease. Lipoproteinassociated phospholipase A 2 is produced by inflammatory cells involved in atherogenesis (macrophages, T cells, mast cells), is predominantly bound to atherogenic lipoproteins, and accumulates in human atherosclerotic lesions (9) . Although this enzyme has been referred to as plateletactivating factor-acetylhydrolase (PAF-AH), Lp-PLA 2 exhibits much broader substrate specificity (10, 11) . In particular, Lp-PLA 2 rapidly degrades polar phospholipids present in oxidized LDL-C, releasing downstream products such as lysophosphatidylcholine species and oxidized nonesterified fatty acids (12) . These products of the Lp-PLA 2 reaction exhibit a wide range of pro-inflammatory and pro-apoptotic effects in experimental settings (9) . In this context, Lp-PLA 2 could be proposed as the enzyme that links oxidized LDL-C with atherosclerosis progression and plaque vulnerability. This hypothesis is supported by studies that suggest increased risk of CV events with elevated levels of circulating Lp-PLA 2 , the presence of high expression of Lp-PLA 2 in apoptotic macrophages in high-risk human coronary lesions, and the ability to alter the phenotype of inflammatory cells with Lp-PLA 2 inhibition in vitro (13) (14) (15) (16) (17) (18) . The view of Lp-PLA 2 as a pro-atherogenic enzyme, however, has not been uniformly accepted, because of contradictory results of Lp-PLA 2 overexpression in preclinical models of atherosclerosis, a theoretical concern that inhibition of Lp-PLA 2 might lead to increase in platelet activation, and conflicting data with a genetic variant of Lp-PLA 2 in Japanese subjects (9, 19) .
In this study, we sought to investigate whether darapladib (SB-480848), a selective Lp-PLA 2 inhibitor, produces sustained inhibition of plasma Lp-PLA 2 activity in CV patients treated aggressively with atorvastatin. In addition, the effects of darapladib on several CV biomarkers of risk and safety were examined.
Methods
Study design. The multicenter, randomized, double-blind, placebo-controlled, parallel-group study that was conducted in 110 sites in 15 countries from November 2005 to June 2006 (a list of investigators is provided in the Online Appendix). This doseranging study evaluated the ability of darapladib to produce sustained inhibition of plasma Lp-PLA 2 activity in subjects with stable coronary heart disease (CHD) or CHD-risk equivalent receiving concomitant atorvastatin therapy. Those subjects not currently receiving statin therapy first received open-label atorvastatin 20 mg for 2 weeks. All eligible subjects were initially randomized to double-blind atorvastatin 20 or 80 mg once daily (Fig. 1) . After 4 weeks, subjects who tolerated atorvastatin therapy and achieved LDL-C levels of Յ115 mg/dl were then randomized to concomitant administration of darapladib 40 mg, 80 mg, 160 mg, or placebo once daily for 12 weeks. After discontinuing darapladib or placebo, subjects continued on double-blind atorvastatin for an additional 2 weeks. Ethics committees approved the protocol, and all subjects provided written informed consent before enrollment in the study. Study subjects. Subjects ages 18 to 80 years with stable CHD or CHD-risk equivalent (defined as diabetes mellitus requiring hypoglycemic medication; carotid stenosis Ͼ50%; prior carotid surgery or stenting; peripheral arterial disease; or a cluster of risk factors resulting in 10-year risk for coronary events Ͼ20% according to Framingham Risk Score) were eligible for screening. Main exclusion criteria were CV event or vascular procedure within the preceding 6 months, contraindications to double-blind atorvastatin therapy, serum triglycerides Ͼ400 mg/dl, elevated liver function tests (alanine transaminase, aspartate transaminase, alkaline phosphatase, or total bilirubin Ͼ1.5 ϫ ULN), hemoglobin subtype A1c Ͼ10%, chronic inflammatory diseases, inadequately controlled hypertension (Ͼ160 mm Hg systolic or Ͼ100 mm Hg diastolic), renal disorder (serum creatinine Ͼ2.5 mg/dl), severe congestive heart failure (New York Heart Association functional class III or IV), and prolonged QTc interval (Ͼ440 ms for men or Ͼ450 ms for women). Assessments. Blood assessments were carried out in the fasting state at baseline (before randomization to darapladib or placebo) and at 4 and 12 weeks of dosing with darapladib or placebo. These included total cholesterol, high-density lipoprotein-cholesterol (HDL-C), calculated LDL-C, tri- PAF-AH ‫؍‬ plateletactivating factoracetylhydrolase glycerides, and routine safety labs. In addition, plasma Lp-PLA 2 activity, inflammatory biomarkers, and plateletrelated biomarkers were measured at baseline and at 4 and 12 weeks approximately 24 h after dosing with darapladib or placebo. Plasma Lp-PLA 2 activity and platelet-related biomarkers were also measured 2 weeks after discontinuing darapladib or placebo. Supine vital signs were collected at baseline, 4, 8, and 12 weeks, and 2 weeks after discontinuing darapladib or placebo; a physical examination and electrocardiogram were also performed at baseline and at 4 and 12 weeks. Biochemical parameters. The Lp-PLA 2 activity was measured in plasma by a colorimetric assay as previously described (20) . The assay characteristics included intra-assay precision of 1.7% and inter-assay precision of 4.8%. In a subset of subjects, Lp-PLA 2 activity also was measured by a radiometric assay with [ 3 H]-platelet-activating factor as a substrate (21) . The assay (Quest Diagnostics, Lyndhurst, New Jersey) included intra-assay precision: low 3.0%, mid 4.5%, high 2.2% and interassay precision: low 6.5%, mid 7.4%, high 8.8%. Details regarding the analysis of the remaining biomarkers are provided online. Statistical analyses. The primary efficacy end point was sustained inhibition of plasma Lp-PLA 2 activity measured as the change from 4 to 12 weeks at trough levels of darapladib. The primary comparison was based on 2-sided 95% confidence intervals (CIs) for the change in logtransformed Lp-PLA 2 activity from week 4 to week 12 for each darapladib group. Sample size was calculated with an SD for change in log-transformed Lp-PLA 2 activity values of 0.34 from a previous study, an equivalence limit of 0.883 to 1.132 (equivalent to Ϯ 0.124 on the log scale), and 90% power. With these assumptions, 196 subjects/group were required, without adjustment for multiplicity or atorvastatin treatment group. Thus, assuming a 15% dropout rate, a minimum of 920 subjects (or 230/treatment group) were planned to be randomized.
Secondary end points included dose-response of darapladib over log-transformed Lp-PLA 2 activity and changes in inflammatory biomarkers and platelet-related biomarkers. Primary and secondary end points of changes in Lp-PLA 2 activity and inflammatory and platelet-related biomarkers were all assessed with analysis of covariance. Treatment group and atorvastatin doses (20 and 80 mg) were included in all statistical models, with baseline values also included for inflammatory and platelet-related biomarkers. Interactions for atorvastatin level by treatment group were tested at the 10% significance level. Correlations were assessed with Pearson product moment correlation coefficients. Figure 1 depicts subject flow through the study. A total of 1,410 subjects were screened for eligibility, 1,082 were assigned to double-blind atorvastatin, and 964 subjects were subsequently randomized to darapladib or placebo. Five of these subjects did not receive any dose of darapladib or placebo; therefore 959 subjects were included in the analyses. The exposure to darapladib or placebo was 81 Ϯ 13 days (mean Ϯ SD).
Results

Study population and baseline characteristics.
Baseline characteristics of the subject population are presented in Table 1 . At study entry, 75% of subjects were Subject Disposition
All eligible subjects were initially randomized to double-blind atorvastatin 20 or 80 mg once daily. After 4 weeks, subjects who tolerated atorvastatin therapy and achieved low-density lipoprotein cholesterol levels of Յ115 mg/dl were then randomized to concomitant administration of darapladib 40 mg, 80 mg, 160 mg, or placebo once daily for 12 weeks. The number of subjects and reason for discontinuation are depicted in this figure.
receiving statin therapy. As required by the protocol, all subjects were assigned atorvastatin and received a high level of contemporary medical care. Demographic data, past medical history, and concomitant treatments were balanced among subgroups of subjects randomized to placebo or the 3 dosing regimens of darapladib. Baseline Lp-PLA 2 activity. As shown in Table 2 , baseline levels of Lp-PLA 2 activity were significantly higher in older subjects, in men, in nondiabetic patients, in those with LDL-C Ն70 mg/dl or HDL-C Ͻ40 mg/dl, in those receiving the lower dose of atorvastatin, and in those with documented vascular disease. Diabetic subjects had lower values of Lp-PLA 2 activity than nondiabetic subjects, likely owing to lower LDL-C levels (diabetic: 64 Ϯ 1 mg/dl vs. nondiabetic: 71 Ϯ 1 mg/dl, p Ͻ 0.001). In the multivariate regression analysis, all of these variables remained statistically significant (p Ͻ 0.01) except for diabetic status. When baseline Lp-PLA 2 activity was examined as a continuous variable, it showed the strongest correlation with baseline levels of total cholesterol (Pearson r ϭ 0.345, p Ͻ 0.0001), LDL-C (r ϭ 0.459, p Ͻ 0.0001), and inverse correlation with HDL-C (r ϭ Ϫ0.229, p Ͻ 0.0001). Baseline levels of Lp-PLA 2 activity and inflammatory biomarkers exhibited weak and nonsignificant correlations. Effects of darapladib on Lp-PLA 2 . As shown in Figure 2 , baseline Lp-PLA 2 activity (colorimetric assay) was comparable among subjects randomized to placebo or darapladib 40, 80, or 160 mg. In placebo-treated subjects, Lp-PLA 2 activity remained unchanged over the study duration. In contrast, there was a clear dose-dependent reduction of Lp-PLA 2 activity after 4 weeks of darapladib dosing (first measurement after randomization), which was also observed at 12 weeks (p Ͻ 0.001 for all doses). When compared with placebo, the observed inhibition of Lp-PLA 2 activity was sustained at approximately 43%, 55%, and 66% for darapladib 40, 80, and 160 mg, respectively. This inhibition corresponded to achieved levels of Lp-PLA 2 activity (nmol/ min/ml) at 12 weeks as follows: placebo: 124 (95% CI 120 to 128), darapladib 40 mg: 68 (95% CI 65 to 71), darapladib 80 mg: 56 (95% CI 53 to 60), and darapladib 160 mg: 43 (95% CI 40 to 45). After darapladib discontinuation (15 Ϯ 4 days), levels of Lp-PLA 2 activity returned toward baseline although they remained lower. In a subset of subjects (n ϭ 323), the enzyme inhibition was confirmed with radiometric assay of Lp-PLA 2 activity that reproduced the shape of dose response. As shown in Online Figure 1 , excellent Pearson correlations between the colorimetric and radiometric assays were found for the percent inhibition from baseline to week 12 (r ϭ 0.97, p Ͻ 0.0001) and between achieved levels of Lp-PLA 2 activity at week 12 (r ϭ 0.96, p Ͻ 0.0001). Lipoprotein-associated phospholipase A 2 mass was also measured in a subset of subjects (n ϭ 228). Darapladib reduced Lp-PLA 2 mass at week 12 compared with placebo (p Ͻ 0.001 for all doses) but without a dose response (9.6%, 12.9%, and 9.3% reductions by darapladib 40, 80, and 160 mg, respectively). Lipid measurements and the effects of darapladib. Treatment with darapladib did not modify total cholesterol, LDL-C, HDL-C, or triglyceride levels at week 4 (not shown) or at week 12 as compared with placebo (Table 3) . Hence, the observed changes in Lp-PLA 2 activity levels in subjects taking darapladib cannot be attributed to changes in lipoprotein carriers of this enzyme. We explored whether atorvastatin dose modified the effect of darapladib on change in Lp-PLA 2 activity at week 12 and found no significant interaction (p ϭ 0.60). We also explored whether baseline LDL-C or HDL-C levels influenced inhibition of Lp-PLA 2 activity over 12 weeks. There was no interaction between baseline LDL-C (Ͻ70 mg/dl vs. Ն70 mg/dl) or HDL-C (Ͻ40 mg/dl vs. Ն40 mg/dl) and the change in Lp-PLA 2 activity at 12 weeks for all darapladib doses (p ϭ 0.12 and p ϭ 0.13, respectively). Within the darapladib 160 mg group, achieved levels of Lp-PLA 2 activity were similar at 12 weeks at different levels of ACE ϭ angiotensin-converting enzyme; ARB ϭ angiotensin receptor blocker; HbA1c ϭ hemoglobin subtype A1c; HDL-C ϭ high-density lipoprotein cholesterol; hs-CRP ϭ high-sensitivity C-reactive protein; IL ϭ interleukin; LDL-C ϭ low-density lipoprotein cholesterol; Lp-PLA 2 ϭ lipoproteinassociated phospholipase A 2 ; MMP-9 ϭ matrix metalloproteinase-9; MPO ϭ myeloperoxidase. In regard to interleukin-6 (IL-6), the greatest reduction was again observed with darapladib 160 mg (n ϭ 150) resulting in 21.5% (95% CI Ϫ28% to Ϫ14%) reduction from baseline (p Ͻ 0.001; within group comparison) and 12.3% (95% CI Ϫ22% to Ϫ1%) when compared with placebo (p ϭ 0.028; between groups comparison) ( Table 4) . When response to darapladib was analyzed post hoc according to quartiles of baseline Lp-PLA 2 activity, darapladib 160 mg (n ϭ 39) reduced IL-6 in the highest quartile by 20.5% (95% CI Ϫ38% to ϩ3%) compared with placebo (n ϭ 42) from 2.62 to 2.12 ng/l versus 2.56 to 2.62 ng/l (p ϭ 0.08). These findings are not likely attributable to treatment-induced changes in body weight, because it remained stable over the course of the study. There were no significant changes in plasma myeloperoxidase and matrix metalloproteinase-9 in any treatment groups (Table 4) .
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Theoretical concern that inhibition of Lp-PLA 2 activity might adversely affect platelet activity prompted us to The results are presented as geometric means with 95% confidence interval. All doses of darapladib produced highly significant inhibition of lipoproteinassociated phospholipase A 2 (Lp-PLA 2 ) activity when compared with placebo at weeks 4 and 12 (p Ͻ 0.001).
Baseline Lp-PLA 2 Activity in Clinical Subgroups examine the effects of darapladib on several biomarkers associated with enhanced platelet aggregation. There was no evidence for the increase in any of the measured platelet biomarkers when analyzed for the changes from baseline (i.e., within group comparison) or in comparison with placebo (i.e., between groups comparison) at week 4 (not shown) and week 12 of treatment with darapladib (Table 5) . Similarly, discontinuation of darapladib produced no significant effect on these measurements at follow-up (not shown). Tables 1 and 2 . Baseline and week 12 data are presented as geometric means. Within group comparisons depict changes from baseline. Between groups comparisons indicate changes from baseline relative to placebo. Within group comparisons were analyzed using paired t test. Between group comparisons were analyzed with analysis of covariance with baseline value, atorvastatin level, and treatment included as covariates. Values in parenthesis are 95% CI. *p Ͻ 0.05; †p ϭ 0.028. Abbreviations as in Tables 1 and 2 .
Effect of Darapladib on Lipid Parameters
Effect of Darapladib on Inflammatory Biomarkers
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Adverse events. There were no clinically important effects on vital signs, electrocardiograms, or laboratory data in the darapladib groups compared with placebo. Serious adverse events were reported in 3% in the placebo (n ϭ 7) and darapladib 40 mg (n ϭ 6) and 80 mg (n ϭ 7) groups and 2% (n ϭ 5) in the darapladib 160 mg group. These events were not concentrated in any particular organ system class and displayed no dose-related pattern. No deaths occurred after randomization to darapladib or placebo. The CV events were infrequent at 2% in the placebo group (n ϭ 4), Ͻ1% in the darapladib 40 and 80 mg groups (n ϭ 2 in both groups), and 1% in the darapladib 160 mg group (n ϭ 3). The most commonly reported serious adverse event was angina at Ͻ1% in the placebo (n ϭ 2) and darapladib 40 mg (n ϭ 1) groups, none in the darapladib 80 mg group, and 1% (n ϭ 3) in the darapladib 160 mg group. A total of 3% (n ϭ 33) of subjects prematurely withdrew from study drug due to an adverse event; 2% (n ϭ 4) in the placebo group, 4% (n ϭ 10) in the darapladib 40 mg group, 3% (n ϭ 8) in the darapladib 80 mg group, and 5% (n ϭ 11) in the darapladib 160 mg group. Within each organ system class, the incidence of adverse events leading to premature withdrawal was Յ1% across all treatment groups with the exception of a 3% (n ϭ 6) incidence of premature withdrawals due to gastrointestinal events (mostly change in feces odor or diarrhea) in the darapladib 160 mg group. A higher incidence of odor-(mainly feces or urine) or tasterelated events was reported in all darapladib treatment groups (33% to 36%) compared with placebo (21%) that did not lead to frequent premature withdrawals (Յ1% incidence of withdrawals due to odor-or taste-related events across all treatment groups).
No cases of rhabdomyolysis or creatine kinase elevation Ͼ10 ϫ upper normal limit were reported. Elevation of alanine transaminase Ն3 ϫ upper limit of normal was noted in Ͻ1% (n ϭ 1) in placebo, Ͻ1% (n ϭ 2) in the darapladib 40 and 80 mg groups, and 1% (n ϭ 3) in the darapladib 160 mg group.
Discussion
Key findings. This is the first report of chronic administration of an Lp-PLA 2 inhibitor, darapladib, in CHD or CHD-risk equivalent patients in the setting of intensive statin therapy. There was a significant dose-dependent and sustained reduction of Lp-PLA 2 activity with darapladib. The effect was independent of baseline LDL-C or HDL-C levels and background atorvastatin regimen. In addition, the results suggested a possible anti-inflammatory effect of the highest dose of darapladib treatment when applied to patients receiving atorvastatin therapy. In regards to safety, there were no adverse effects of darapladib on biomarkers of platelet activity and no major safety concerns emerged from this study. Relationship between Lp-PLA 2 , lipoproteins, and treatment of dyslipidemia. Owing to its binding to carboxylterminus of human apolipoprotein B, approximately 80% of circulating Lp-PLA 2 , measured as mass or activity, is associated with apolipoprotein B-containing lipoproteins (22, 23) . The remaining Lp-PLA 2 is less firmly associated with phospholipid moiety of HDL-C and does not bind to apolipoprotein A-I. Higher Lp-PLA 2 mass or activity are found in pro-atherogenic small dense LDL-C and electronegative LDL-C particles, as opposed to large buoyant LDL-C and electropositive subfractions, respectively (24 -26) . Consistent with this distribution of Lp-PLA 2 , our findings show strong correlations between Lp-PLA 2 activity and LDL-C and inverse relationship with HDL-C in patients on intensive atorvastatin treatment. Prior studies have also shown that various hypolipidemic drugs (e.g., statins, fenoEffect of Darapladib on Platelet-Related Biomarkers fibrate, ezetimibe) decrease plasma Lp-PLA 2 mass or activity due to LDL-C lowering, without a direct effect on macrophage expression of the enzyme (27, 28) . Comparisons across studies are difficult, because of the use of several methods to measure Lp-PLA 2 mass or activity. In general, however, statin treatment alone (e.g., pravastatin, fluvastatin, simvastatin, atorvastatin) has been associated with approximately 20% to 30% reduction in the measurements of Lp-PLA 2 (mass or activity) in stable CV patients (29 -31) . Similarly, other lipid modifying drugs, such as ezetimibe and fenofibrate, modestly lower Lp-PLA 2 (mass or activity) (32) . This study shows that a specific Lp-PLA 2 inhibitor, darapladib, produces substantial additional reductions in Lp-PLA 2 activity when added to intensive atorvastatin therapy (up to 66%). This effect was largely independent of atorvastatin dose and preserved in clinically relevant strata of LDL-C and HDL-C values.
Relationship between Lp-PLA 2 and inflammatory biomarkers. Oxidatively truncated phospholipids are substrates for Lp-PLA 2 that promote formation of putative pro-inflammatory and pro-apoptotic products (9) . The concentration of oxidized LDL-C within human atheroma is approximately 70-fold higher than in circulation; thus, the comparisons between Lp-PLA 2 and other inflammatory markers in plasma might not accurately reflect intralesional inter-dependency (33) . In this context, it is not surprising that circulating Lp-PLA 2 shows weak correlations with other inflammatory biomarkers, as shown in this and previous studies (34, 35) . Nonetheless, increasing levels of Lp-PLA 2 have been reported to have additive effects with hs-CRP or oxidized phospholipid/apolipoprotein B ratio in predicting the risk of CV events (14, 16, 36) . When assessing the effects of Lp-PLA 2 inhibition on soluble inflammatory biomarkers, it is important to underscore that baseline hs-CRP levels were lower in this study compared with other investigations using intensive atorvastatin treatment and therefore might have minimized the opportunity to observe additional effects on this biomarker (5, 6, 37, 38) . Despite these caveats, a significant reduction in hs-CRP was noted in the highest darapladib group (160 mg) after 12 weeks of treatment (within group comparison). Interestingly, the darapladib 160 mg group also exhibited a significant reduction in IL-6 (within group and between groups comparisons). This finding is noteworthy, because IL-6 is a trigger for hepatic production of hs-CRP and it is less affected by background atorvastatin treatment (37, 39) . Relationship between Lp-PLA 2 and PAF. Initial descriptions of Lp-PLA 2 focused on the ability of this enzyme to degrade PAF, a potent pro-inflammatory lipid mediator that is also implicated in platelet aggregation (10) . However, responsiveness to PAF is not altered in Japanese subjects with a genetic variant in Lp-PLA 2 (Val276Phe) that results in the absence of circulating enzyme (40) . In addition, other clinical trials failed to show measurable benefit of recombinant human Lp-PLA 2 in conditions suspected to be PAFmediated (e.g., severe sepsis, asthma) (41,42). These observations together suggested that other extra-and intracellular enzymatic pathways are involved in hydrolysis of PAF, independent of Lp-PLA 2 activity. To this end, studies identified several PAF inactivating enzymes, including lecithin-cholesterol acetyl transferase and unrelated phospholipases (e.g., group X secretory PLA 2 and intracellular PAF-AH [II]) (43, 44) . These findings provide mechanistic explanation for the lack of detrimental effect of darapladib on platelet biomarkers despite high levels of Lp-PLA 2 inhibition. The importance of our findings is also underscored by the fact that several biomarkers were studied, including urinary 11-dehydrothromboxane B 2 , which is less affected by pre-analytical artifacts associated with the measurements of circulating markers (45) . Study limitations. There are several limitations of this study to be emphasized. First, the clinical relevance of the observed Lp-PLA 2 inhibition with darapladib must await evidence linking Lp-PLA 2 inhibition to a beneficial effect on clinical events. Nonetheless, marked inhibition of the enzyme activity in the presence of intensive background statin therapy is an important pre-requisite for testing this concept in high-risk CV patients. Second, our study cannot address the effects of Lp-PLA 2 inhibition within atheroma that is postulated to be ultimately responsible for clinical benefits. It is important to underscore, however, that comparable exposures of darapladib inhibit intralesional Lp-PLA 2 activity in the clinical setting (46) . Third, the effects on IL-6 and hs-CRP were modest and limited to the highest dose of darapladib. These results might be viewed as hypothesis-generating and will require replication in other studies.
Conclusions
Although treatment with statins has resulted in improved prognosis in primary and secondary prevention populations, high-risk individuals continue to experience recurrent CV events despite adequate treatment. It is postulated that inflammatory mediators not addressed by LDL-C lowering contribute to plaque instability and thrombotic events. The results of this study indicate that darapladib produces substantial inhibition of Lp-PLA 2 activity in the presence of intensive statin therapy and suggest that such intervention might result in additional systemic anti-inflammatory effects. Future studies are required to determine whether chronic Lp-PLA 2 inhibition will stabilize high-risk lesions and potentially reduce CV events.
